145397-26-8

Usage

Uses

Used in Pharmaceutical Industry:
5-fluoro-1-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)cytosine is used as a reverse transcriptase enantiomer antiviral for its potential to inhibit the replication of certain viruses, particularly those that rely on reverse transcriptase for their life cycle.
Used in Antiviral Applications:
As a nucleoside, 5-fluoro-1-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)cytosine serves as a potential anti-HIV agent. It may be effective in treating HIV by interfering with the virus's ability to replicate and spread within the host.
Used in Research and Development:
5-fluoro-1-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)cytosine is also used as an analogue of Emtricitabine (E525000) in the development of new antiviral drugs. Its unique structure may provide insights into the design of more effective and targeted therapies for viral infections, including HIV.

InChI:InChI=1/C8H10FN3O4/c9-4-1-12(8(14)11-7(4)10)5-3-15-6(2-13)16-5/h1,5-6,13H,2-3H2,(H2,10,11,14)

Upstream product

• 146996-29-4 (+)-(2S,4S)-N⁴-benzoyl-1-<2-<(benzoyloxy)methyl>-1,3-dioxolan-4-yl>-5-fluorocytosine 
• 192581-99-0 (2S)-2-((benzyloxy)methyl)-1,3-dioxolan-4-yl acetate 
• 146996-30-7 (+)-(2S,4R)-N⁴-benzoyl-1-<2-<(benzoyloxy)methyl>-1,3-dioxolan-4-yl>-5-fluorocytosine 
• 307002-00-2 (2R)-2-benzyloxymethyl-4-acetoxy-1,3-dioxolane 

Relevant academic research and scientific papers

BASE-MODIFIED CYTIDINE NUCLEOTIDES FOR LEUKEMIA THERAPY

Compounds of the formula I wherein X is a bond or -CH2, and pharmaceutically acceptable salts thereof are useful in the parenteral treatment of leukemia, myelodysplastic syndrome or lymphoma, especially in patients presenting with cytarabine re

DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER

The invention provides compounds of formula (I), wherein: R1 is OR11, or NR5R5'; R2 is H or F; R5 is H, C1-C6alkyl, OH, C(=O)R6, O(C=O)R6 or O(C=O)OR6; R5′ is H or C1-C6alkyl; R6 is C1-C6alkyl or C3-C7cycloalkyl; R13 is H, phenyl, pyridyl, benzyl, indolyl or naphthyl wherein the phenyl, pyridyl, benzyl, indolyl and naphthyl is optionally substituted with 1, 2 or 3 R22; and the other variables are as defined in the claims, which are of use in the treatment of cancer, and related aspects.

Synthesis of enantiomerically pure D-FDOC, an anti-HIV agent

The d-enantiomer of FDOC was obtained in optically pure form via a tandem kinetic resolution/chiral salt crystallization protocol. In addition, conditions were developed that allowed the unwanted l-enantiomer to be racemized and recycled. The β-d-enantiomer of FDOC (2′,3′-dideoxy-5-fluoro- oxacytidine) exhibits potent anti-HIV-1 activity. It was obtained in optically pure form by employing a tandem kinetic resolution/chiral salt crystallization protocol. In addition, conditions were developed that allowed the unwanted butyrate ester of the l-enantiomer of FDOC to be racemized. This material could then be recycled in future resolutions.

Method for the treatment of Flaviviridea viral infection using nucleoside analogues

In accordance with the present invention there is provided a method for treating or preventing a Flaviviridea viral infection in a host comprising administering a therapeutically effective amount of at least one compound of formula (I) or (II) or a pharma

Structure-activity relationships among a new class of antiviral heterosubstituted 2',3'-dideoxynucleoside analogues

3'-Oxa-4'-thiocytidine nucleoside analogues 14-17 were prepared from oxathiolanes 10 and 11, and evaluated for activity against HIV-1 and HBV in vitro. The nucleoside analogues were found to possess potent activities against HIV-1 in a panel of cell lines. Compound 16 is moderately active against HBV in 2.2.15 cells.

L-β-(2S,4S)- and L-α-(2S,4R)-dioxolanyl nucleosides as potential anti- HIV agents: Asymmetric synthesis and structure-activity relationships

In order to study the structure-activity relationships of L-(2S,4S)- and L-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents, various enantiomerically pure L-(2S,4S)- and (2S,4R)-dioxolanylpyrimidine and - purine nucleosides have been synthesize